Synthesis, in silico, in vitro, and in vivo investigation of 5-[ 11C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2

European Journal of Medicinal Chemistry

Volumn 58, Issue , 2012, Pages 272-280

  Caballero, Julio ^a   Muñoz, Camila ^a   Alzate Morales, Jans H ^a   Cunha, Susana ^b   Gano, Lurdes ^b   Bergmann, Ralf ^c   Steinbach, Joerg ^c   Kniess, Torsten ^c  

^a UNIVERSIDAD DE TALCA   (Chile)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Carbon 11; Docking; MM GBSA; Molecular dynamics; Radiolabeling; Sunitinib ; VEGFR

Indexed keywords

CARBON 11; FLUORINE; OXINDOLE; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BLOOD FLOW; CELL PROLIFERATION; COMPUTER MODEL; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KNOEVENAGEL CONDENSATION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; RAT; STATIC ELECTRICITY;

CARBON ISOTOPES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84868248820     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.10.020     Document Type: Article

References (39)

1. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
2. W.P. Leenders, B. Küsters, and R.M. de Waal Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis Endothelium 9 2002 83 87
3. N. Ferrera Vascular endothelial growth factor: basis science and clinical progress Endocr. Rev. 25 2004 581 611
4. M. Shibuya, and L. Claesson-Welsh Signal transduction by VEGF receptors in regulation of angiogenesis and lymphagogenesis Exp. Cell. Res. 312 2006 549 560
5. J.W. Hicks, H.F. Van Brocklin, A.A. Wilsom, S. Houle, and N. Vasdev Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT Molecules 15 2010 8260 8278
6. M.H. Michalski, and X. Chen Molecular imaging in cancer treatment Eur. J. Nucl. Med. Mol. Imaging 38 2011 358 377
7. V. Tolmachev, S. Stone-Elander, and A. Orlova Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls Lancet Oncol. 11 2010 992 1000
8. R. Haubner, H.J. Wester, W.A. Weber, and M. Schwaiger Radiotracer-based strategies to image angiogenesis Q. J. Nucl. Med. 47 2003 189 199
9. R. Haubner, and H.J. Wester Radiolabeled tracers for imaging tumor angiogenesis and evaluation of anti-angiogenic therapies Curr. Pharm. Des. 10 2004 1439 1455
10. 11C]PAO as PET imaging tracer for VEGFR-2 Eur. J. Nucl. Med. Mol. Imaging 36 2009 1283 1295
11. O. Ilovich, O. Jacobson, Y. Aviv, A. Litchi, R. Chisin, and E. Mishani Formation of fluorine-18 labeled diaryl ureas - labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogénesis Bioorg. Med. Chem. 16 2008 4242 4251
12. 11C]-urea derivatives as potential PET angiogenic probes J. Label. Compd. Radiopharm. 52 2009 151 157
13. 11C]phosgene as a labeling agent J. Label. Compd. Radiopharm. 54-S1 2011 S96
14. 11C]sorafenib, a tyrosine kinase inhibitor PET tracer to be used in cancer therapy J. Label. Compd. Radiopharm. 54-S1 2011 S85
15. D. Dischino, T. Tran, D. Donelly, S. Bonascorsi, P. Chow, R. Roache, D. Kukral, J. Kim, and W. Hayes J. Label. Compd. Radiopharm. 54-S1 2011 S444
16. O. Ilovich, H. Billauer, S. Dotan, and E. Mishani Labeled 3-aryl-4-indolylmaleimide derivatives and their potential as angiogenic PET biomarkers Bioorg. Med. Chem. 18 2010 612 620
17. 18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase Bioorg. Med. Chem. Lett. 15 2005 4380 4384
18. T. Kniess, R. Bergmann, M. Kuchar, J. Steinbach, and F. Wuest Synthesis and radiopharmacological investigation of 3-[4′-[18F]fluorobenzylidene]- indolin-2-one as possible tyrosine kinase inhibitor Bioorg. Med. Chem. 17 2009 7733 7742
19. C. Muñoz, F. Adasme, J.H. Alzate-Morales, A. Vergara-Jaque, T. Kniess, and J. Caballero Study of differences in the VEGFR-2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations J. Mol. Graph. Model. 32 2012 39 48
20. 125I]iodo-sunitinib Bioorg. Med. Chem. Lett. 2012 10.1016/j.bmcl.2012.02.068
21. E. Giovannini, and P. Portmann Sur quelques derives de l'oxindole et de l'isatine. II. Sur les amino-, hydroxy- et méthoxy-dérivés substitués en position 5 et 6 Helv. Chim. Acta 31 1948 1381 1391
22. N. Itoh, T. Sakamoto, E. Miyazawa, and Y. Kikugawa Introduction of a hydroxyl group at the para position and N-iodophenylation of N-arylamides using phenyliodine(III)bis(trifluoroacetate) J. Org. Chem. 67 2002 7424 7428
23. G. Lakshmaiah, T. Kawabata, M. Shang, and K. Fuji Total synthesis of (-)-horsfiline via asymmetric nitroolefination J. Org. Chem. 64 1999 1699 1704
24. L. Sun, C. Liang, S. Shirazian, Y. Zhou, T. Miller, J. Cui, J.Y. Fukuda, J.Y. Chu, A. Nematalla, X. Wang, H. Chen, A. Sistla, T.C. Luu, F. Tang, J. Wei, and C. Tang Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]- 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J. Med. Chem. 46 2003 1116 1119
25. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749
26. J.H. Alzate-Morales, A. Vergara-Jaque, and J. Caballero Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site J. Chem. Inf. Model. 50 2010 1101 1112
27. Maestro, Version 9.0 2007 Schrödinger, LLC New York, NY
28. G.A. Kaminski, R.A. Friesner, J. Tirado-Rives, and W.L. Jorgensen Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 105 2001 6474 6487
29. K.J. Bowers, E. Chow, H. Xu, R.O. Dror, M.P. Eastwood, B.A. Gregersen, J.L. Klepeis, I. Kolossvary, M.A. Moraes, F.D. Sacerdoti, J.K. Salmon, Y. Shan, and D.E. Shaw Proceedings of the 2006 ACM/IEEE Conference on Supercomputing 2006 ACM Tampa, Florida 84
30. MacroModel, Version 9.5 2007 Schrödinger, LLC New York, NY
31. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J. Mol. Graph. 14 1996 33 38
32. M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Cireci, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.M. Lelias, S.A. Metha, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, and D.J. Lockhart A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23 2005 329 336
33. D.B. Mendel, D.A. Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.Ö. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, and J.M. Cherrington In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamics relationship Clin. Cancer Res. 9 2003 327 337
34. K.S. Gajiwala, J.C. Wu, J. Christensen, G.D. Deshmukh, W. Diehl, J.P. DiNitto, J.M. English, M.J. Greig, Y.A. He, S.L. Jacques, E.A. Lunney, M. McTigue, D. Molina, T. Quenzer, P.A. Wells, X. Yu, Y. Zhang, A. Zou, M.R. Emmett, A.G. Marshall, H.-M. Zhang, and G.D. Demetri KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc. Natl. Acad. Sci. U.S.A. 106 2009 1542 1547
35. P.A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T. Lee, Y. Duan, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D.A. Case, and T.E. Cheatham 3rd Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models Acc. Chem. Res. 33 2000 889 997
36. P. Zhou, J. Lv, J. Zou, F. Tian, and Z. Shang Halogen-water-hydrogen bridges in biomolecules J. Struct. Biol. 169 2010 172 182
37. Y. Lu, Y. Wang, Z. Xu, X. Yan, X. Luo, H. Jiang, and W. Zhu C-X⋯H Contacts in biomolecular systems: how they contribute to protein-ligand binding affinity J. Phys. Chem. B 113 2009 12615 12621
38. 11C-methane production in small volume, high pressure gas targets Radiochem. Acta 88 2000 201 205
39. 11C-methane J. Label. Compd. Radiopharm. 37 1995 73 75